PE20001089A1 - Metodo para incrementar la dureza y resistencia osea - Google Patents

Metodo para incrementar la dureza y resistencia osea

Info

Publication number
PE20001089A1
PE20001089A1 PE1999000839A PE00083999A PE20001089A1 PE 20001089 A1 PE20001089 A1 PE 20001089A1 PE 1999000839 A PE1999000839 A PE 1999000839A PE 00083999 A PE00083999 A PE 00083999A PE 20001089 A1 PE20001089 A1 PE 20001089A1
Authority
PE
Peru
Prior art keywords
pth
increases
parathyroid hormone
resistance
increase bone
Prior art date
Application number
PE1999000839A
Other languages
English (en)
Spanish (es)
Inventor
Janet M Hock
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26792729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20001089(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20001089A1 publication Critical patent/PE20001089A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Steroid Compounds (AREA)
PE1999000839A 1998-08-19 1999-08-19 Metodo para incrementar la dureza y resistencia osea PE20001089A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9715198P 1998-08-19 1998-08-19
US9974698P 1998-09-10 1998-09-10

Publications (1)

Publication Number Publication Date
PE20001089A1 true PE20001089A1 (es) 2000-11-04

Family

ID=26792729

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000839A PE20001089A1 (es) 1998-08-19 1999-08-19 Metodo para incrementar la dureza y resistencia osea

Country Status (32)

Country Link
US (2) US6977077B1 (enExample)
EP (3) EP2266598B1 (enExample)
JP (5) JP2002523375A (enExample)
KR (1) KR100454207B1 (enExample)
CN (1) CN1205997C (enExample)
AR (1) AR033639A1 (enExample)
AT (1) ATE231000T1 (enExample)
AU (1) AU746277B2 (enExample)
BR (1) BR9909445A (enExample)
CA (1) CA2325371C (enExample)
CO (1) CO5130020A1 (enExample)
CY (2) CY1113343T1 (enExample)
CZ (1) CZ301017B6 (enExample)
DE (2) DE15152726T1 (enExample)
DK (4) DK1769804T3 (enExample)
DZ (1) DZ2873A1 (enExample)
EA (1) EA003362B1 (enExample)
ES (4) ES2393200T3 (enExample)
HR (1) HRP20000755A2 (enExample)
HU (2) HU230697B1 (enExample)
ID (1) ID29039A (enExample)
IL (2) IL138829A0 (enExample)
MY (1) MY129227A (enExample)
NO (2) NO323984B1 (enExample)
NZ (1) NZ507056A (enExample)
PE (1) PE20001089A1 (enExample)
PL (1) PL201688B1 (enExample)
PT (4) PT2907522T (enExample)
TR (1) TR200003455T2 (enExample)
TW (1) TW576747B (enExample)
UA (1) UA72205C2 (enExample)
WO (1) WO2000010596A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
AR033639A1 (es) * 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
EP1222465A1 (en) * 1999-09-20 2002-07-17 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
MXPA04006728A (es) * 2002-01-10 2005-08-19 Osteotrophin Llc Tratamiento de desordenes oseos con medicamentos anabolicos esqueleticos.
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
CA2539357A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
MXPA06012980A (es) * 2004-05-10 2007-06-12 Nastech Pharm Co Composiciones y metodos para el suministro mucosal mejorado de la hormona paratiroidea.
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
EP1744683B1 (en) 2004-05-13 2016-03-16 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
US7648965B2 (en) 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US20060069021A1 (en) * 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
CN101217972B (zh) * 2005-05-11 2013-05-29 尤尼基因实验室公司 促进骨形成和保持的方法
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
BRPI0618469A2 (pt) * 2005-11-10 2011-08-30 Univ Michigan Tech hormÈnio paratiróide de urso preto e métodos de uso de hormÈnio paratiróide de urso preto
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20080119408A1 (en) * 2006-07-07 2008-05-22 Nastech Pharmaceutical Company Inc. Pth formulations for intranasal delivery
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
EP2537539B1 (en) 2007-04-13 2019-04-03 Kuros Biosurgery AG Polymeric Tissue Sealant
US20110137243A1 (en) * 2007-09-06 2011-06-09 Abbott Cardiovascular Systems Inc. Coating On A Balloon Device
US9457056B2 (en) * 2007-12-04 2016-10-04 Ben-Gurion University Of The Negev Research And Development Authority Peptides comprising alternating hydrophobic and anionic amino acids for treatment of osteoporosis
EP2227263A2 (en) 2007-12-28 2010-09-15 Kuros Biosurgery AG Pdgf fusion proteins incorporated into fibrin foams
KR20190095552A (ko) 2009-09-09 2019-08-14 아사히 가세이 파마 가부시키가이샤 1회당 100∼200 단위의 pth가 주 1회 투여되는 것을 특징으로 하는, pth 함유 골다공증 치료/예방제
EP2509996A1 (en) 2009-12-07 2012-10-17 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9295663B2 (en) 2010-07-14 2016-03-29 Abbott Cardiovascular Systems Inc. Drug coated balloon with in-situ formed drug containing microspheres
WO2012111852A1 (ja) * 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
ES2882852T3 (es) 2011-03-16 2021-12-02 Kuros Biosurgery Ag Formulación farmacéutica para la utilización en la fusión espinal
ES2833277T3 (es) 2011-06-07 2021-06-14 Asahi Kasei Pharma Corp Preparación liofilizada que contiene PTH de alta pureza y método para producirla
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
WO2017136195A1 (en) 2016-02-01 2017-08-10 Eli Lilly And Company Parathyroid hormone – anti-rankl antibody fusion compounds
CN110520148A (zh) * 2017-02-01 2019-11-29 约翰霍普金斯大学 甲状旁腺激素与退行性椎间盘疾病的再生
JP6577683B2 (ja) * 2017-09-22 2019-09-18 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
WO2020090174A1 (ja) 2018-10-29 2020-05-07 旭化成ファーマ株式会社 週2回の頻度でテリパラチド又はその塩を投与することを特徴とする、骨粗鬆症の予防又は治療方法
US12344649B2 (en) 2019-08-09 2025-07-01 Flagship Pioneering Innovations Vi, Llc Modulators of parathyroid hormone receptor (PTHR1)
GB2590692A (en) * 2019-12-24 2021-07-07 Corthotec Ltd Composition for improved bone fracture healing

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
DE3935738A1 (de) 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
US5208041A (en) 1991-05-23 1993-05-04 Allelix Biopharmaceuticals Inc. Essentially pure human parathyroid hormone
US5556940A (en) 1994-06-20 1996-09-17 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
JPH0873376A (ja) 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
CA2205959A1 (en) * 1994-12-19 1996-06-27 Michael Chorev Continuous low-dose administration of parathyroid hormone or its agonist
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
SK76797A3 (en) * 1994-12-22 1998-02-04 Astra Ab Therapeutic preparation for inhalation containing parathyroid hormone, pth
JPH08310965A (ja) * 1995-05-16 1996-11-26 Chugai Pharmaceut Co Ltd 骨癒合促進剤
TR200000649T2 (tr) * 1997-09-09 2000-09-21 F.Hoffmann-La Roche Ag PTHrP analogları kullanılarak kırıkların iyileştirilmesi.
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
AR033639A1 (es) 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US20040033950A1 (en) 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
US6907597B1 (en) 2000-10-13 2005-06-14 Ati International Srl Method and apparatus for constructing an executable program in memory
US6967759B2 (en) 2001-12-31 2005-11-22 Texas Instruments Incorporated Pulse width modulation sequence generation
JP5796714B2 (ja) 2012-01-13 2015-10-21 株式会社リコー 定着装置及び画像形成装置
EP2949301B1 (en) 2014-05-27 2018-04-18 The Procter and Gamble Company Absorbent core with curved and straight absorbent material areas

Also Published As

Publication number Publication date
CY1113343T1 (el) 2016-06-22
ATE231000T1 (de) 2003-02-15
NO20005947D0 (no) 2000-11-24
ES2393200T3 (es) 2012-12-19
ES2621653T3 (es) 2017-07-04
HUP0101594A2 (hu) 2001-11-28
DK2266598T3 (en) 2017-05-15
US6977077B1 (en) 2005-12-20
CN1308545A (zh) 2001-08-15
JP2017190332A (ja) 2017-10-19
DK2907522T1 (da) 2015-10-19
IL138829A0 (en) 2001-10-31
ES2549551T1 (es) 2015-10-29
IL138829A (en) 2011-01-31
PT1769804E (pt) 2012-11-13
CO5130020A1 (es) 2002-02-27
ES2190244T3 (es) 2003-07-16
NO323984B1 (no) 2007-07-30
KR20010072763A (ko) 2001-07-31
ID29039A (id) 2001-07-26
PL201688B1 (pl) 2009-04-30
TW576747B (en) 2004-02-21
EP2266598A1 (en) 2010-12-29
CN1205997C (zh) 2005-06-15
NZ507056A (en) 2003-10-31
HU230697B1 (hu) 2017-09-28
EP1059933A1 (en) 2000-12-20
AU746277B2 (en) 2002-04-18
DK2907522T3 (en) 2017-10-23
EP1059933B1 (en) 2003-01-15
NO20072983L (no) 2000-11-24
PT1059933E (pt) 2003-06-30
CY1119552T1 (el) 2018-03-07
BR9909445A (pt) 2000-12-12
EA003362B1 (ru) 2003-04-24
HK1030545A1 (en) 2001-05-11
HK1212602A1 (en) 2016-06-17
JP2015028065A (ja) 2015-02-12
EP2907522A1 (en) 2015-08-19
ES2549551T3 (es) 2017-11-27
TR200003455T2 (tr) 2001-06-21
AR033639A1 (es) 2004-01-07
DE15152726T1 (de) 2015-12-10
PT2266598T (pt) 2017-05-02
JP2014139220A (ja) 2014-07-31
HU1200430D0 (hu) 2001-11-28
PL343595A1 (en) 2001-08-27
DE69904918T2 (de) 2003-11-13
CA2325371A1 (en) 2000-03-02
AU5575099A (en) 2000-03-14
WO2000010596A1 (en) 2000-03-02
HUP0101594A3 (en) 2002-01-28
CZ20004134A3 (cs) 2001-08-15
US20050197294A1 (en) 2005-09-08
JP2002523375A (ja) 2002-07-30
UA72205C2 (uk) 2005-02-15
PT2907522T (pt) 2017-10-23
JP2011021035A (ja) 2011-02-03
DK1059933T3 (da) 2003-04-07
CZ301017B6 (cs) 2009-10-14
DK1769804T3 (da) 2012-10-15
NO20005947L (no) 2000-11-24
MY129227A (en) 2007-03-30
HK1102496A1 (en) 2007-11-23
HRP20000755A2 (en) 2001-02-28
DZ2873A1 (fr) 2003-12-15
JP6177718B2 (ja) 2017-08-09
EP2266598B1 (en) 2017-02-22
EP2907522B1 (en) 2017-08-02
KR100454207B1 (ko) 2004-10-26
US7163684B2 (en) 2007-01-16
CA2325371C (en) 2004-08-17
EA200001015A1 (ru) 2001-02-26
DE69904918D1 (de) 2003-02-20

Similar Documents

Publication Publication Date Title
PE20001089A1 (es) Metodo para incrementar la dureza y resistencia osea
US10022165B2 (en) Orthopedic fastener device
US8617585B2 (en) Intramedullary drug delivery device and method of treating bone fractures
de Vries et al. Treatment of subtrochanteric nonunions
WO2002034148A3 (en) Systems and methods for reducing fractured bone using a fracture reduction cannula
ATE318559T1 (de) Vorrichtungen zur behandlung von gebrochenen und/oder erkrankten knochen
Gadegone et al. Long proximal femoral nail in ipsilateral fractures proximal femur and shaft of femur
Gadegone et al. Short proximal femoral nail fixation for trochanteric fractures
CA2343378A1 (en) Fracture fixation system
ZICKEL et al. Zickel supracondylar nails for fractures of the distal end of the femur
Frölke et al. ĮDESTINATION OF DEBRIS DURING INTRAMEDULLARY REAMING AN EXPERIMENTAL, STUDY (ON SHEEP PEMURS
WO2015137911A1 (en) Orthopedic fastener device
Speed et al. The treatment of malunited Colles's fractures
Wroblewski et al. Wear of enhanced ultra-high molecular-weight polyethylene (Hylamer) in combination with a 22.225 mm diameter zirconia femoral head
Patil et al. Role of Cemented Bipolar Hemiarthroplasty for Comminuted Inter-trochanteric Femur Fracture in elderly osteoporotic patients through a modified Transtrochanteric approach—“SION Hospital Modification”
Leung Reconstruction of a large femoral defect using a vascular pedicle iliac graft. Case report.
Bisbinas et al. Reamer breakage in the femoral medulla during total knee arthroplasty: should reamers have a finite life?
RU2837475C1 (ru) Способ лечения пациента с несостоятельным дистракционным костным регенератом в стадии оссификации
WO2016063193A1 (en) Intertrochanteric fixation device
Kurdy et al. The Huckstep Nail: Stable Fixation of Mechanically Deficient Femoral Bone.
Cantlon et al. Calcium phosphate cement augmentation of proximal humerus fractures
Phemister Aseptic Necrosis of Bone Management and Prognosis
Shrestha et al. Intramedullary pinning for surgical correction of condylar fracture in a dog
Goh et al. Augmentation of Osteoarticular Allograft Reconstruction With Photodynamic Nail for the Management of Primary or Recurrent Aggressive Giant Cell Tumor in the Distal Radius
Misra Implantology of Fractures of the Shaft of Femur Including Segmental and Combination Fractures

Legal Events

Date Code Title Description
FC Refusal